Abstract: Pharmaceutical compositions comprising cholestenoic acids and deuterated derivatives thereof, methods of treatment or prevention of neurodegenerative conditions, as well as diagnostic methods and novel biomarkers form aspects of the invention.

Abstract: The invention relates to methods for determining whether a subject is afflicted with a motor neuron disease, the method comprising conducting an analysis of cerebrospinal fluid and/or plasma, measuring the level of one or more sterol/oxysterol analytes, and comparing these to reference values. Further, the invention relates to methods of identifying agents suitable for the treatment of MND, and monitoring the progress of the disease.

Abstract: Pharmaceutical compositions comprising cholestenoic acids and deuterated derivatives thereof, methods of treatment or prevention of neurodegenerative conditions, as well as diagnostic methods and novel biomarkers form aspects of the invention.

Abstract: The present invention relates to methods for the diagnosis or prognosis of conditions caused by defects in cholesterol bio synthesis, such as Smith-Lemli-Opitz syndrome (SLOS), in particular to early diagnostic methods including in utero methods.

Abstract: The invention relates to methods for determining whether a subject is afflicted with a motor neuron disease, the method comprising conducting an analysis of cerebrospinal fluid and/or plasma, measuring the level of one or more sterol/oxysterol analytes, and comparing these to reference values. Further, the invention relates to methods of identifying agents suitable for the treatment of MND, and monitoring the progress of the disease.

Abstract: A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. in particular, the reagent is a cholestenoic acid of a particular form, such as 3?,7?-dihydroxycholest-5-en-26-oic (3?,7?-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

Abstract: A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3?,7?-dihydroxycholest-5-en-26-oic (3?,7?-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

Abstract: Compounds of general formula (I) wherein (I) RI-R4 are each independently selected from H and deuterium; and at least one of RI-R4 is deuterium. The compounds have been found to be particularly useful for treating neurodegenerative conditions and in particular but not exclusively conditions such as motor neurone disease.

Abstract: The present invention relates to methods for the diagnosis or prognosis of conditions caused by defects in cholesterol biosynthesis, such as Smith-Lemli-Opitz syndrome (SLOS), in particular to early diagnostic methods including in utero methods.

Abstract: The invention relates to a kit and methods for quantitative detection of steroids in a sample. The kit comprises quantitative charge tags and an oxidizing agent.

Abstract: Compounds of general formula (I) wherein (I) R1-R4 are each independently selected from H and deuterium; and at least one of R1-R4 is deuterium. The compounds have been found to be particularly useful for treating neurodegenerative conditions and in particular but not exclusively conditions such as motor neurone disease.

Abstract: The present invention provides an agitator for agitating a liquid (e.g. an electrolyte solution) containing particles (e.g. abrasive particles) within a tank. The agitator comprises an agitator body having an upper surface and a lower surface with at least one aperture extending through the agitator body. There is a one-way valve for allowing liquid flow through at least one aperture from the upper surface to the lower surface and for blocking liquid flow through at least one aperture from the lower surface to the upper surface.

Abstract: A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3?,7?-dihydroxycholest-5-en-26-oic (3?,7?-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

Abstract: The invention relates to a kit and methods for quantitative detection of steroids in a sample. The kit comprises quantitative charge tags and an oxidising agent.

Abstract: An apparatus (60) for applying a dry film lubricant comprises a tool (62) and a pad (64). The tool (62) includes a handle (66), a cranked member (68) and a supporting member (70). The pad (64) is removably locatable on the supporting member (64). The supporting member (70) is oval in cross-section and the pad (64) includes an oval cross-section hollow member removably locatable on the supporting member (70). The supporting member (70) comprises locking means (78) to lock the pad (64) on the supporting member (70). The supporting member (70) comprises positioning means (80) to position the pad (64) on the supporting member (70). The tool (62) also has a shielding member (72) spaced from and arranged parallel to the supporting member (70). The handle (66) is arranged in a plane (A) substantially parallel to a plane (B) containing the supporting member (70) and to a plane (C) containing the shielding member (72). The pad (64) is substantially dovetail shape in cross-section to correspond to a rotor slot (40).

Abstract: A system and method for marketing automobiles. In one aspect of the invention, a website for marketing automobiles, the website comprising functionality as disclosed in FIGS. 9, 10, 12, and 13, alone or in combination. In another aspect of the invention, a world wide web enabled computer system is provided, the computer system comprising: a processor for hosting a website, the website comprising functionality as disclosed in FIGS. 9, 10, 12, and 13, alone or in combination; and a storage means, wherein the storage means is operably coupled to the processor, and wherein the storage means is used to host a plurality of partitions, the plurality of partitions comprise an automobile buyers' partition, an administration partition, and a automobile dealer's partition.

Abstract: This invention involves the identification of a ligand for the retinol X receptor. Specifically docosahexaenoic has been identified as an RXR ligand. Various assays based upon this observation are a feature of this invention.